Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Assisted Therapy for Prolonged Grief
NCT06724289Phase 1Recruiting
- Sponsor
- University of Virginia
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in prolonged grief disorder (PGD), sponsored by University of Virginia. Primary endpoints: Recruitment Rate and Dropout Rate. Started Mar 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
prolonged grief disorder (PGD)
Beyond the preview
Go deeper on NCT06724289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724289.